- Home
- OXBR vs EVAX Comparison
OXBR vs EVAX Comparison
Compare OXBR & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OXBR
- EVAX
- Stock Information
- Founded
- OXBR 2013
- EVAX 2008
- Country
- OXBR Cayman Islands
- EVAX Denmark
- Employees
- OXBR N/A
- EVAX N/A
- Industry
- OXBR Property-Casualty Insurers
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OXBR Finance
- EVAX Health Care
- Exchange
- OXBR Nasdaq
- EVAX Nasdaq
- Market Cap
- OXBR 15.1M
- EVAX 17.8M
- IPO Year
- OXBR 2014
- EVAX 2021
- Fundamental
- Price
- OXBR N/A
- EVAX $6.29
- Analyst Decision
- OXBR Strong Buy
- EVAX Strong Buy
- Analyst Count
- OXBR 1
- EVAX 2
- Target Price
- OXBR $5.00
- EVAX $11.00
- AVG Volume (30 Days)
- OXBR 76.1K
- EVAX 4.4M
- Earning Date
- OXBR 11-12-2025
- EVAX 10-30-2025
- Dividend Yield
- OXBR N/A
- EVAX N/A
- EPS Growth
- OXBR N/A
- EVAX N/A
- EPS
- OXBR N/A
- EVAX N/A
- Revenue
- OXBR $1,983,000.00
- EVAX $3,176,000.00
- Revenue This Year
- OXBR $497.99
- EVAX N/A
- Revenue Next Year
- OXBR $42.14
- EVAX $425.50
- P/E Ratio
- OXBR N/A
- EVAX N/A
- Revenue Growth
- OXBR N/A
- EVAX 1042.45
- 52 Week Low
- OXBR $1.27
- EVAX $1.20
- 52 Week High
- OXBR $5.81
- EVAX $15.50
- Technical
- Relative Strength Index (RSI)
- OXBR 50.07
- EVAX 67.86
- Support Level
- OXBR $1.75
- EVAX $3.70
- Resistance Level
- OXBR $2.09
- EVAX $7.23
- Average True Range (ATR)
- OXBR 0.18
- EVAX 0.66
- MACD
- OXBR -0.03
- EVAX 0.27
- Stochastic Oscillator
- OXBR 28.85
- EVAX 70.78
About OXBR Oxbridge Re Holdings Limited
Oxbridge Re Holdings Ltd is a specialty property and casualty reinsurer. It provides reinsurance solutions through its subsidiary. It focuses on underwriting fully collateralized reinsurance contracts for property and casualty insurance companies in the Gulf Coast region of the United States, with an emphasis on Florida. Oxbridge specializes in underwriting medium frequency, high severity risks, where insufficient data exists to analyze effectively the risk/return profile of reinsurance contracts. The company manages its business on the basis of one operating segment, Property and Casualty Reinsurance.
About EVAX Evaxion Biotech
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.